Schering-Plough
This article was originally published in The Rose Sheet
Executive Summary
Robert Bertolini tapped exec VP and CFO, effective Nov. 17, company announces. Reporting to CEO Fred Hassan, Bertolini will be responsible for building a global finance team dedicated to transforming Schering into a successful international competitor, firm says. Exec, who previously served as a lead partner in PricewaterhouseCoopers' Global Pharmaceutical Industry Group, succeeds Jack Wyszomierski, who is leaving the firm to pursue other interests. Bertolini's appointment is "an important step" in implementing Schering's turnaround plan, according to the company (1"The Rose Sheet" July 14, 2003, p. 9)...
You may also be interested in...
Schering Taps Former AHP Exec Barshay To Head Consumer Health Care Unit
Schering-Plough appointed former American Home Products Senior VP Stanley Barshay as chairman of its Consumer Health Care division effective July 7
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.